GlassScriptPhysician profile
Guy F Miller
NPI 1457426751
$535.10
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $433 · 2020: $102.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $157.66 | 2019 | |
| Lilly USA, LLC | $65.43 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.48 | 2019 | |
| Amgen INC. | $45.97 | 2019 | |
| Novo Nordisk INC | $45.80 | 2019 | |
| Allergan, INC. | $28.97 | 2020 | |
| Alfasigma USA, INC. | $17.44 | 2020 | |
| Novartis Pharmaceuticals Corporation | $16.88 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $15.89 | 2019 | |
| Amarin Pharma, INC. | $14.90 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $13.44 | 2019 | |
| Merck Sharp & Dohme LLC | $13.40 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.86 | 2020 | |
| Abbvie INC. | $11.97 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.01 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guy Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.